// App-Quantinova.ai

OP34 : VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis

Researchers

Presenter

  • Stefan Schreiber

Principal Investigators

  • Laurent Peyrin-Biroulet

  • Edward V Loftus, Jr

  • Silvio Danese

  • Jean-Frederic Colombel

  • Brihad Abhyankar

  • Jingjing Chen

  • Raquel Rogers

  • Richard A Lirio

  • Jeffrey D Bornstein

  • Bruce E Sands

Medical Centers

  • University Hospital Schleswig-Holstein, Lubeck, Germany

  • Nantes University Hospital, Nantes, France

  • Mayo Clinic College of Medicine, Rochester, MN

  • Humanitas University, Rozzano, Italy

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Takeda Development Centre Europe Ltd., London, UK

  • Takeda Development Center Americas Inc., Cambridge, USA

Locations

  • Germany

  • France

  • United States

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Entyvio

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

  • Dose Escalation

Phase

  • III

Study Id's

  • NCT02497469

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved